SCHEMBL30920444

SCHEMBL30920444

CC1(C(=O)NCc2cc3cc(F)c(O)cc3[nH]2)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CA12 O43570 2/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA2 P00918 2/20 0.33
▸ CA9 Q16790 2/20 0.33
▸ METTL3 Q86U44 6/20 0.33
▸ METTL14 Q9HCE5 6/20 0.33
▸ IKBKB O14920 1/20 0.31
▸ RET P07949 1/20 0.31
▸ APOL1 O14791 1/20 0.31
▸ DRD1 P21728 1/20 0.31
▸ DRD4 P21917 1/20 0.31
▸ DRD3 P35462 1/20 0.31
▸ TMEM97 Q5BJF2 1/20 0.31
▸ SIGMAR1 Q99720 1/20 0.31
▸ METAP2 P50579 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27246917 1.00 RAB9A (0.43) RAB9ANPC1SMN1; SMN2CA12CA1
SCHEMBL27247588 0.88 RAB9A (0.38) RAB9ANPC1SMN1; SMN2CA12CA1
SCHEMBL30920136 0.88 RAB9A (0.38) RAB9ANPC1SMN1; SMN2CA12CA1
SCHEMBL27383632 0.87 RAB9A (0.42) RAB9ANPC1SMN1; SMN2METTL3METTL14
SCHEMBL30920545 0.87 RAB9A (0.42) RAB9ANPC1SMN1; SMN2METTL3METTL14
SCHEMBL27247781 0.86 RAB9A (0.40) RAB9ANPC1SMN1; SMN2CA12CA1
SCHEMBL30920251 0.85 SMN1; SMN2 (0.38) RAB9ANPC1SMN1; SMN2CA12CA1
SCHEMBL27247646 0.85 SMN1; SMN2 (0.38) RAB9ANPC1SMN1; SMN2CA12CA1
SCHEMBL30920406 0.85 SMN1; SMN2 (0.43) RAB9ANPC1SMN1; SMN2CA12CA1
SCHEMBL27246735 0.85 SMN1; SMN2 (0.43) RAB9ANPC1SMN1; SMN2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4601635-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF Maze Therapeutics, Inc. (US) 2025-08-20 — — EP disclosed
Send feedback